RxSight (RXST) Competitors $9.04 -0.11 (-1.20%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$9.12 +0.08 (+0.93%) As of 08/29/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXST vs. NVCR, SSII, ESTA, CDRE, BLFS, PLSE, MDXG, KMTS, INMD, and IRMDShould you be buying RxSight stock or one of its competitors? The main competitors of RxSight include NovoCure (NVCR), SS Innovations International (SSII), Establishment Labs (ESTA), Cadre (CDRE), BioLife Solutions (BLFS), Pulse Biosciences (PLSE), MiMedx Group (MDXG), Kestra Medical Technologies (KMTS), InMode (INMD), and iRadimed (IRMD). These companies are all part of the "medical equipment" industry. RxSight vs. Its Competitors NovoCure SS Innovations International Establishment Labs Cadre BioLife Solutions Pulse Biosciences MiMedx Group Kestra Medical Technologies InMode iRadimed NovoCure (NASDAQ:NVCR) and RxSight (NASDAQ:RXST) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Does the media prefer NVCR or RXST? In the previous week, RxSight had 23 more articles in the media than NovoCure. MarketBeat recorded 26 mentions for RxSight and 3 mentions for NovoCure. NovoCure's average media sentiment score of 0.84 beat RxSight's score of 0.45 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 5 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate NVCR or RXST? NovoCure currently has a consensus target price of $28.79, suggesting a potential upside of 133.46%. RxSight has a consensus target price of $10.00, suggesting a potential upside of 10.62%. Given NovoCure's stronger consensus rating and higher possible upside, research analysts plainly believe NovoCure is more favorable than RxSight.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57RxSight 2 Sell rating(s) 8 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.91 Is NVCR or RXST more profitable? RxSight has a net margin of -21.93% compared to NovoCure's net margin of -27.13%. RxSight's return on equity of -11.56% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-27.13% -47.74% -13.79% RxSight -21.93%-11.56%-10.31% Which has more volatility and risk, NVCR or RXST? NovoCure has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, RxSight has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Do institutionals & insiders believe in NVCR or RXST? 84.6% of NovoCure shares are held by institutional investors. Comparatively, 78.8% of RxSight shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 9.6% of RxSight shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger earnings and valuation, NVCR or RXST? RxSight has lower revenue, but higher earnings than NovoCure. RxSight is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$630.16M2.19-$168.63M-$1.56-7.90RxSight$139.93M2.64-$27.45M-$0.80-11.30 SummaryRxSight beats NovoCure on 9 of the 16 factors compared between the two stocks. Get RxSight News Delivered to You Automatically Sign up to receive the latest news and ratings for RXST and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXST vs. The Competition Export to ExcelMetricRxSightMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$369.92M$6.89B$5.69B$9.74BDividend YieldN/A1.13%6.64%4.48%P/E Ratio-11.3026.1883.1926.59Price / Sales2.6471.66515.16159.07Price / CashN/A22.4425.6628.92Price / Book1.304.9611.766.08Net Income-$27.45M$176.38M$3.27B$265.93M7 Day Performance4.99%1.34%1.13%0.36%1 Month Performance15.90%4.21%8.30%5.58%1 Year Performance-83.97%7.54%62.26%19.67% RxSight Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXSTRxSight1.5506 of 5 stars$9.04-1.2%$10.00+10.6%-84.0%$369.92M$139.93M-11.30220NVCRNovoCure3.9312 of 5 stars$11.70-5.9%$28.79+146.0%-36.6%$1.39B$605.22M-7.501,488SSIISS Innovations InternationalN/A$6.98-0.1%N/AN/A$1.35B$20.65M0.004ESTAEstablishment Labs1.6849 of 5 stars$40.66-6.8%$56.50+39.0%-9.9%$1.26B$177.42M-13.331,018CDRECadre2.74 of 5 stars$30.27-2.5%$31.50+4.0%-14.9%$1.26B$567.56M32.212,284Positive NewsBLFSBioLife Solutions2.2386 of 5 stars$25.65-1.0%$31.29+22.0%-3.2%$1.24B$82.25M-213.73440Positive NewsPLSEPulse Biosciences3.9516 of 5 stars$16.49-3.3%$22.00+33.4%-16.6%$1.15B$700K-15.70140MDXGMiMedx Group3.8713 of 5 stars$7.08-3.1%$12.00+69.5%+3.8%$1.08B$348.88M33.72870Positive NewsKMTSKestra Medical Technologies1.2084 of 5 stars$17.72-4.6%$27.33+54.3%N/A$953.80M$59.81M0.00300News CoveragePositive NewsLockup ExpirationINMDInMode2.2005 of 5 stars$14.57-1.6%$18.04+23.8%-10.6%$936.13M$394.82M5.90480Positive NewsIRMDiRadimed4.7418 of 5 stars$71.50-1.6%$72.00+0.7%+54.3%$924.23M$73.24M44.14110Positive News Related Companies and Tools Related Companies NovoCure Alternatives SS Innovations International Alternatives Establishment Labs Alternatives Cadre Alternatives BioLife Solutions Alternatives Pulse Biosciences Alternatives MiMedx Group Alternatives Kestra Medical Technologies Alternatives InMode Alternatives iRadimed Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXST) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersNew Banking Law #1582 Could Unlock $21 Trillion for AmericansDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RxSight, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RxSight With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
